Skip to content
Triangle logo TriangleGet started
← Full study record

NCT01383759 · OUTCOME

Organ Response - Cardiac Involvement at 24 Months

Bortezomib/Dexamethasone (BD), Followed By Autologous Stem Cell Transplantation and Maintenance Bortezomib/Dexamethasone For the Initial Treatment of Monoclonal Immunoglobulin Deposition Disease (MIDD) Associated With Multiple Myeloma and AL Amyloidosis · Source last updated 2020-04-07

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
COUNT_OF_PARTICIPANTS
Unit
Participants
Interval / dispersion
Not reported
Time frame
24 months

What was measured

24 months post-initiation of treatment following the 3 phase comprehensive treatment approach including induction with BD, followed by risk adapted HDM/ASCT, followed by consolidation/maintenance therapy with BD in patients with AL amyloidosis.

Groups in this outcome

Amyloidosis

Participants with newly diagnosed AL amyloidosis

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
Amyloidosis19

Reported measurements

Source class 1

Participants without cardiac involvement

Values in Participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Amyloidosis7Not reportedNot reportedNot reportedNot reported

Cardiac involvement, improved

Values in Participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Amyloidosis8Not reportedNot reportedNot reportedNot reported

Cardiac involvement, progressed

Values in Participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Amyloidosis2Not reportedNot reportedNot reportedNot reported

Cardiac involvement, died during induction

Values in Participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Amyloidosis2Not reportedNot reportedNot reportedNot reported
Complete source fields
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        value
        7
      title
      Participants without cardiac involvement
    2. measurements
      1. group Id
        OG000
        value
        8
      title
      Cardiac involvement, improved
    3. measurements
      1. group Id
        OG000
        value
        2
      title
      Cardiac involvement, progressed
    4. measurements
      1. group Id
        OG000
        value
        2
      title
      Cardiac involvement, died during induction
denoms
  1. counts
    1. group Id
      OG000
      value
      19
    units
    Participants
description
24 months post-initiation of treatment following the 3 phase comprehensive treatment approach including induction with BD, followed by risk adapted HDM/ASCT, followed by consolidation/maintenance therapy with BD in patients with AL amyloidosis.
groups
  1. description
    Participants with newly diagnosed AL amyloidosis
    id
    OG000
    title
    Amyloidosis
param Type
COUNT_OF_PARTICIPANTS
reporting Status
POSTED
time Frame
24 months
title
Organ Response - Cardiac Involvement at 24 Months
type
SECONDARY
unit Of Measure
Participants

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice